COMMUNIQUÉS West-GlobeNewswire
-
Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé
23/08/2024 - 04:06 -
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
22/08/2024 - 22:40 -
Ovarian Cancer Canada announces its annual Walk of Hope to support Canadians facing ovarian cancer
22/08/2024 - 22:37 -
Vision Sensing Acquisition Corp. Announces Letter of Intent with Convergence CT, Inc.
22/08/2024 - 22:35 -
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024
22/08/2024 - 22:30 -
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
22/08/2024 - 22:30 -
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
22/08/2024 - 22:30 -
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
22/08/2024 - 22:30 -
Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
22/08/2024 - 22:15 -
BrightSpring Health Services, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
22/08/2024 - 22:05 -
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
22/08/2024 - 22:05 -
NeuroPace to Participate in Upcoming Healthcare Conferences in September
22/08/2024 - 22:05 -
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
22/08/2024 - 22:05 -
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
22/08/2024 - 22:03 -
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
22/08/2024 - 22:00 -
CORRECTION -- InnovAge PACE Celebrates Anniversary of Vibrant Sacramento Center
22/08/2024 - 21:20 -
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
22/08/2024 - 20:15 -
Six-month interim report (Q2) 2024
22/08/2024 - 17:49 -
ALK upgrades its full-year revenue and earnings outlook
22/08/2024 - 17:38
Pages